ClinicalTrials.gg
CompletedNCT06003400TriO FITTUpdated Oct 8, 2026

Proof of Concept Open Label, Clinical Trial to Evaluate the Safety and Efficacy of the "FITT" Device in Diabetic Foot Ulcers Patients

An interventional study of Study treatment administration (TriO FITT) and Physical Examination in Diabetic Foot Ulcer, sponsored by Tri.O Medical LTD. Completed at 1 site in Israel. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Tri.O Medical LTD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2023, registered Jul 2023).
Updated Oct 8, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Diabetic Foot with a site in Israel — none open to participants now, 2 under way, none of them phase 3. Diabetic Foot · Israel.

Enrollment
16th of 18
19 · median 25
Started
2023
with 1 other
No phase
8 of 21
none open now
Registered
20th of 21
by date

Among the 21 studies in Diabetic Foot with a site in Israel, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 20th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

None of the 21 studies in Diabetic Foot with a site in Israel is open now. The open studies under Diabetic Foot, anywhere →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Diabetic Foot with a site in Israel as a file.
02

Study summary

The TriO FITT device is designed to improve the symptoms of chronic diabetic ulcers.

The mechanism of action of the device optimizes and combines the administration known supproting treatments to chronic diabetic ulcers. The treatment is astimated to improve the wound conditions of acute and chronic diabetic wounds.

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 18-80 years old
  • Chronic Diabetes Mellitus type 1 and type 2 diagnosed at least 3 years before the screening
  • Have a single non-infected diabetic hard-to-heal wound (ulcers/foot ulcers) ≤ 0.8-40 cm2 wound area at start of treatment, for period of at least for 3 months.
  • Wagner classification stage 1 or 2 or post-debridement stage 3.
  • At least moderate blood perfusion into the affected limb as defined by Ankle Brachial Index (ABI) ≥0.65
  • Stable diabetic drugs 4 weeks before Screening
  • Be available for the entire study period, and be able and willing to adhere to protocol requirements
  • Provide written prior to admission into the study

Exclusion criteria

Exclusion Criteria:

  • Have a glycosylated () > 10.5%
  • Have more than one wound
  • Have a (BMI) > 40 kg/m2
  • Have visible bone exposure at wound site
  • Anemia (Hemoglobin \< 9 g/dL) or White Blood Cells count > 11,000/μL or count \< 100,000/μL or liver function tests > 3 times upper normal lab values or Creatinine > 3 mg/dL; any indication of malnourishment (Albumin \< 3 g/dL); >2 or any other blood and urinalysis tests per the physician's discretion
  • Patients with unstable hypertension
  • Have any clinically significant chronic or acute illness during the 4 weeks prior to admission into the study, except diabetes type 1 or 2 or during screening period
  • Females who are pregnant, lactating, of , or for less than 2 years, not using a medically approved method of (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test
  • Participation in a clinical study or use of an drug within 30 days prior to admission to this study
  • Patients with active Gangrenous foot ulcers
  • Active osteomyelitis (Have any signs of infection in the wound (which could be linked to raised body temperature), abscess, cellulitis, necrosis, erythema, mild drainage or known osteomyelitis)
  • Patients with uncontrolled hyperthyroidism
  • Patients with history of collagen diseases
  • Patients with known allergy to ozone
  • Anxiety, Depression, history of Mental illness or patient under Guardian
  • Any medical condition for which the investigator deems the subject unable to participate in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Tri.O FITT

    The study patients will undergo a screening period of upto 4 weeks, a traetment period of upto 12 weeks and a follow-up period of upto 12 additional weeks.

    Device: Study treatment administration (TriO FITT) · Diagnostic Test: Physical Examination · Diagnostic Test: Vital Signs · Diagnostic Test: Hematology Blood Tests · Diagnostic Test: Biochemistry Blood Test · Diagnostic Test: Wound Digital Photography · Diagnostic Test: Urine pregnancy test · Other: Visual Analogue Scale · Other: SF-36 · Diagnostic Test: Wounds evaluation

Interventions

  • DeviceStudy treatment administration (TriO FITT)

    Patients will be treated with the study device 2-3 times per week (determined by their wagner score) for an hour at each visit. treatment will include a combination of methods (the exact details is patented by the company and can not be elaborated).

  • Diagnostic testPhysical Examination

    physical examination will include an overall examination of the patient's body for any iregular findings and or physical changes from baseline.

  • Diagnostic testVital Signs

    vital signs measurement will include blood pressure, pulse and oral temperature as well as hight and weight.

  • Diagnostic testHematology Blood Tests

    complete CBC, coagulogram (PT, aPTT); D-dimer; C-reactive protein;; Ferritin; fibrinogen,

  • Diagnostic testBiochemistry Blood Test

    urea, creatinine, uric acid, sodium, potassium, chloride, calcium, glucose, glycated hemoglobin, alkaline phosphatase (FA), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin and fractions ( BTF), total proteins and fractions (PTF), lipid profile (total cholesterol, fractions and triglycerides).

  • Diagnostic testWound Digital Photography

    3 photographs of the wound taken before wash, after wash and after treatment.

  • Diagnostic testUrine pregnancy test

    for women with childbearing potential

  • OtherVisual Analogue Scale

    Visual Analogue Scale - visual scale scoring 1-10 measuring pain, 10 being worst pain.

  • OtherSF-36

    SF-36 - quality of life questionnaire scaling from 0-100, 100 being best quality of life.

  • Diagnostic testWounds evaluation

    including size measurements and visual description.

06

What researchers measure

Primary outcomes

  1. Safety measured by number of patients who lack adverse events throughout the study.

    Time frame: 0 to 28 weeks

  2. Change in pain level between visits 1 and the last treatment evaluated by VAS scale

    pain levels will be measured by the precent of change in VAS pain raiting scale.

    Time frame: 0 to 28 weeks

  3. Change in Quality of life (QoL) between visits 1 and the last treatment, measured by SF-36

    score measures from 0 to 100, 100 being good quality of life.

    Time frame: 0 to 28 weeks

  4. Change in wound size between V1 and the last treatment

    change in size (cm\^2)

    Time frame: 0 to 28 weeks

07

Study locations

1 site
  • Hilel Yafe Medical Center
    Hadera, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Nov 2025, 31 months.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 31 months is above that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Dec 2025 → Nov 2025 and completion Jan 2026 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 22, 2023
StartActual
Mar 29, 2023
Primary completionActual
Nov 23, 2025was Dec 2025
CompletionActual
Dec 1, 2025was Jan 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 8, 2026
Primary completion
Dec 2025→Nov 23, 2025 (actual)
Oct 8, 2026
Study completion
Jan 2026→Dec 1, 2025 (actual)
Oct 8, 2026
Enrollment
20 (estimated)→19 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Active, not recruiting→Completed
    Primary completion Dec 2025→Nov 23, 2025 (now actual)
    Study completion Jan 2026→Dec 1, 2025 (now actual)
    Enrollment 20 (estimated)→19 (actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06003400
Lead sponsor
Tri.O Medical LTD
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Mar 29, 2023
Primary completion
Nov 23, 2025
Completion
Dec 1, 2025
Last update
Oct 8, 2026

Study contacts

Ronen Ben Ari
study director · CEO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion